Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.27 | N/A | -101.59% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.27 | N/A | -101.59% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding the current financial outlook. They emphasized ongoing efforts to enhance operational efficiency.
Management did not provide specific guidance for future performance.
The company is focusing on strategic initiatives to improve operations.
The earnings report indicates significant challenges for Soleno Therapeutics, particularly reflected in the EPS miss. The stock's slight decline of 0.24% suggests that investors are reacting to the lack of guidance and the negative earnings figure. Without clear direction from management, uncertainty may persist in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PUBLIC STORAGE REIT
Feb 24, 2025